Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNAi-based treatment for geographic atrophy
- Development stage
- Preclinical
- Lead developer
- City Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
A novel RNAi-based therapeutic approach being developed through a strategic collaboration between City Therapeutics and Bausch + Lomb for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This therapy utilizes RNA interference technology to potentially address the underlying mechanisms of GA progression, offering a different approach from the complement inhibition mechanism used by currently approved treatments.
Beyond the preview
Go deeper on RNAi-based treatment for geographic atrophy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNAi-based treatment for geographic atrophy.